A novel frameshift mutation in ADCK1 identified in a case of chronic fatigue syndrome successfully treated with oral 5-ALA/SFC 2024 Koga et al

Discussion in 'ME/CFS research' started by Andy, Dec 27, 2024.

  1. Andy

    Andy Committee Member

    Messages:
    23,401
    Location:
    Hampshire, UK
    Abstract

    Chronic Fatigue Syndrome (CFS) is a complex disorder characterized by prolonged, unexplained fatigue and challenging diagnosis. We report the case of a 35-year-old Japanese woman with CFS who had experienced chronic fatigue since the age of 11 years. Despite treatment with modafinil, methylphenidate, levocarnitine, and ubiquinone, the symptoms persisted.

    Introduction of oral 5-aminolevulinic acid with sodium ferrous citrate (5-ALA/SFC) led to significant improvements in daily activities, mobility, and psychosocial functioning. Genetic analysis revealed a novel heterozygous frameshift deletion in ADCK1 (p.Asn280fs), a gene related to mitochondrial function, which was confirmed using cDNA sequencing. ADCK1 deficiency has been associated with developmental disabilities, mitochondrial dysfunction, increased reactive oxygen species levels, and apoptosis in Drosophila and muscle cells. This case supports the hypothesis that ADCK1 mutations contribute to mitochondrial dysfunction and CFS pathogenesis.

    The patient’s significant clinical improvement with 5-ALA/SFC and ubiquinone suggests their potential for addressing mitochondrial dysfunction. Further functional and familial analyses are required to confirm the role of this heterozygous ADCK1 mutation in CFS. This case highlights the importance of considering mitochondrial dysfunction in CFS, and the potential therapeutic benefits of 5-ALA/SFC and ubiquinone.

    Open access, https://www.tandfonline.com/doi/full/10.1080/25785826.2024.2445399#d1e200
     
    shak8, Yann04, NelliePledge and 7 others like this.
  2. Chris Ponting

    Chris Ponting Established Member (Voting Rights)

    Messages:
    81
    Location:
    Edinburgh
    Every human on earth carries deleterious changes to their genes. This person has several such changes, and the authors focus on only 1, to ADCK1, and to only one of their two copies of the ADCK1 gene.
    Notably, there is not evidence for deleterious changes to the ADCK1 gene being linked to any human disease (including ME/CFS) or trait, from the AstraZeneca analysis of UK Biobank data: https://azphewas.com/geneView/6319c068-fd59-46d8-85ee-82d82482eb14/ADCK1/glr/binary.
    So without any further supporting evidence my view is that this observation is unproved.
     

Share This Page